Your session is about to expire
← Back to Search
Epcoritamab + R-CHOP for Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-2 Trial)
EPCORE DLBCL-2 Trial Summary
This trial will study an investigational drug, epcoritamab, to assess its effect on disease activity in people with a form of cancer called diffuse large B-cell lymphoma (DLBCL). 900 participants will be enrolled in 315 sites globally.
EPCORE DLBCL-2 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowEPCORE DLBCL-2 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.EPCORE DLBCL-2 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I can provide a recent tumor sample for the study.I can perform daily activities with little to no assistance before starting R-CHOP treatment.I have been diagnosed with a specific type of lymphoma called CD20+ DLBCL.I am scheduled for 6 cycles of R-CHOP treatment.I have a serious heart condition.I have had treatment for DLBCL, excluding certain steroids or palliative radiotherapy.I have a tumor visible on scans and it's active on a PET scan.My lymphoma does not include specific high-risk types like Hodgkin's or Burkitt.
- Group 1: Epcoritamab and R-CHOP
- Group 2: R-CHOP and Rituximab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this research involve participants that are 20 or older?
"The age range that is able to enroll in this clinical trial, as specified by the eligibility criteria, is 18 to 79 years old."
How does the safety profile of R-CHOP and Rituximab compare to other similar treatments?
"The safety of R-CHOP and Rituximab was given a score of 3. This is based on the fact that this is a Phase 3 trial - meaning that there is efficacy data as well as multiple rounds of data in support of safety."
Is this research still enrolling new participants?
"The clinical trial in question is no longer looking for participants, as indicated by the fact that it was last updated over 8 months ago. However, there are 1807 other studies that are still recruiting patients."
Who meets the qualifications to participate in this clinical trial?
"This clinical trial is looking for 900 participants that have diffuse large b-cell lymphoma (dlbcl). The patients must be 18-79 years old and meet the following criteria: They must be planned to receive treatment with 6 cycles of standard rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP) per investigator determination., DLBCL, Not Otherwise Specified (NOS)., High grade B-cell lymphoma with MYC and BCL-2 and/or BCL-6 rearrangement with"
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Share this study with friends
Copy Link
Messenger